Reuters logo
Biota's influenza drug fails in mid-stage study
August 1, 2014 / 11:12 AM / 3 years ago

Biota's influenza drug fails in mid-stage study

Aug 1 (Reuters) - Biota Pharmaceuticals Inc said its experimental influenza drug failed to meet the main goal in a mid-stage study.

The drug, Laninamivir octanoate, is undergoing development to treat influenza A and B infections. (Reporting by Natalie Grover in Bangalore; Editing by Savio D‘Souza)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below